Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/21/2012WO2012080236A1 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080234A1 Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080232A1 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080230A1 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080229A1 Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
06/21/2012WO2012080228A1 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080151A1 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
06/21/2012WO2012079578A1 Selective killing of cancer cells
06/21/2012WO2012079532A1 Dicoumarol-like compounds and preparation method and use thereof
06/21/2012WO2012079232A1 Compounds used for treating cancer and the use thereof
06/21/2012WO2012079154A1 Selective estrogen receptor modulators
06/21/2012WO2012079128A1 Thiosemicarbazone compounds and use in the treatment of cancer
06/21/2012WO2012061113A3 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
06/21/2012WO2012053768A3 Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
06/21/2012WO2012040323A3 Multimeric il-15 soluble fusion molecules and methods of making and using same
06/21/2012WO2012038504A3 Breast cancer therapeutics
06/21/2012WO2012031205A3 Lipid-polymer hybrid particles
06/21/2012WO2012026820A3 Immunotherapeutic method for treating prostate cancer
06/21/2012WO2012021512A3 Erythrocyte-binding therapeutics
06/21/2012WO2011145035A8 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
06/21/2012WO2011119925A3 Synthetic herpes simplex viruses for treatment of cancers
06/21/2012WO2011051540A9 Androgen receptor modulating compounds
06/21/2012US20120159657 Compositions and Methods for Inhibiting Expression of RRM2 Genes
06/21/2012US20120159655 Methods using axl as a biomarker of epithelial-to-mesenchymal transition
06/21/2012US20120157550 Drug carriers comprising amphilphilic block copolymers
06/21/2012US20120157542 Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
06/21/2012US20120157539 Nuclear receptor binding agents
06/21/2012US20120157520 Dioxanes derived from regrouping carbohydrates and c-glycosides, process for obtaining same and uses thereof
06/21/2012US20120157518 Sublingual Spray Formulation Comprising Dihydroartemesinin
06/21/2012US20120157517 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof
06/21/2012US20120157510 Controlling The Potential Of Primate Neural Stem Cells By Regulating Pax6
06/21/2012US20120157508 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
06/21/2012US20120157507 USP47 Inhibtors and Methods to Induce Apoptosis
06/21/2012US20120157505 Oral formulations of bendamustine
06/21/2012US20120157499 Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
06/21/2012US20120157495 Benzimidazole derivatives
06/21/2012US20120157494 Isoindolyl compounds
06/21/2012US20120157489 Treatment of endometriosis
06/21/2012US20120157481 Tricyclic pyrimidine derivatives as wnt antagonists
06/21/2012US20120157480 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
06/21/2012US20120157479 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
06/21/2012US20120157473 Therapeutic methods and compounds
06/21/2012US20120157472 Method for treating colorectal cancer
06/21/2012US20120157471 Benzimidazole derivatives
06/21/2012US20120157470 Salts and crystalline forms of an apoptosis-inducing agent
06/21/2012US20120157468 Plk inhibitor salts
06/21/2012US20120157465 Dna methylation inhibitors
06/21/2012US20120157461 Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer
06/21/2012US20120157456 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
06/21/2012US20120157455 Compounds And Compositions For Treating Cancer
06/21/2012US20120157454 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
06/21/2012US20120157453 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157452 1h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinase
06/21/2012US20120157451 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157443 Bruton's tyrosine kinase inhibitors
06/21/2012US20120157442 Heteroaryl btk inhibitors
06/21/2012US20120157441 Inhibitors of the mutant form of kit
06/21/2012US20120157439 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157437 Vla-4 inhibitory drug
06/21/2012US20120157433 Heteroaryl Compounds as Kinase Inhibitors
06/21/2012US20120157431 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
06/21/2012US20120157430 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
06/21/2012US20120157429 Compounds useful as inhibitors of janus kinases
06/21/2012US20120157428 Bromodomain inhibitors and uses thereof
06/21/2012US20120157426 Mutant-selective egfr inhibitors and uses thereof
06/21/2012US20120157418 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses
06/21/2012US20120157414 Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
06/21/2012US20120157412 Substituted Pyrimidinyl Oxime Kinase Inhibitors
06/21/2012US20120157403 Bicyclic and tricyclic derivatives as thrombin receptor antagonists
06/21/2012US20120157402 Methods for treating brain tumors
06/21/2012US20120157400 Methods for treating kaposi sarcoma
06/21/2012US20120157390 IAP Inhibitors
06/21/2012US20120157389 Peptides for treating cancer
06/21/2012US20120157384 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity
06/21/2012US20120157373 Antimicrobial compounds having protective or therapeutic leaving groups
06/21/2012US20120156732 Useful polypeptides
06/21/2012US20120156312 Compositions for Inhibiting Growth of Cancer Stem Cells
06/21/2012US20120156310 Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
06/21/2012US20120156305 Methods for enhancing genome stability and telomere elongation in embryonic stem cells
06/21/2012US20120156289 Biodegradable Osmotic Pump Implant For Drug Delivery
06/21/2012US20120156284 Enhanced biological autologous tissue adhesive composition and methods of preparation and use
06/21/2012US20120156282 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
06/21/2012US20120156280 Myeloid derived suppressor cell inhibiting agents
06/21/2012US20120156251 Cationic oil-in-water emulsions
06/21/2012US20120156247 Biocomposition stimulant of the immune system, anti-tumour and anti-hiv
06/21/2012US20120156246 Reprogramming cancer cells
06/21/2012US20120156233 Vaccine therapy for choroidal neovascularization
06/21/2012US20120156231 Foxm1 peptides and vaccines containing the same
06/21/2012US20120156227 Proteins modified with (amino) monosaccharide-biotin adduct
06/21/2012US20120156226 Marker Differentially Expressed in Cancer Stem Cells and Methods of Using Same
06/21/2012US20120156225 Method of therapy
06/21/2012US20120156224 Modulation of tim receptor activity in combination with cytoreductive therapy
06/21/2012US20120156223 Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens
06/21/2012US20120156219 Nitrogen-containing heterocyclic compounds and medicinal use thereof
06/21/2012US20120156218 Novel anti-cd38 antibodies for the treatment of cancer
06/21/2012US20120156217 Novel EGFR-Binding Molecules and Immunoconjugates Thereof
06/21/2012US20120156216 Methods and Compositions for Treatment of Tumor Metastasis
06/21/2012US20120156213 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor
06/21/2012US20120156212 Methods and compositions for treating neoplasia
06/21/2012US20120156207 Methods and compositions for inhibiting cd32b expressing cells
1 ... 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 ... 2211